Fig. 1: MAPK pathway inhibition enhances immune response in BRAFV600E CRC.
From: Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
a, Tumor baseline T cell signature expression levels in confirmed responders (R) (n = 8) and nonresponders (NR) (n = 39) from a clinical trial of dabrafenib/trametinib/panitumumab in patients with BRAFV600E CRC (DTP treatment arm only, two-tailed Wilcoxon rank sum tests). b, Levels of immune signatures (T cell, cytotoxic T cell and phagocytic) in 45 paired day 1 and day 15 biopsies from a clinical trial of dabrafenib/trametinib/panitumumab (all DTP, DP and TP treatment arms, two-tailed Wilcoxon rank sum tests). a,b, The box plots show the median, first and third quartiles (Q1 and Q3) (25th and 75th percentiles) of the data. The upper and lower whiskers extend to the minimum and maximum values no further than 1.5× the interquartile range, respectively; outliers are plotted individually. c, Tumor volume of C57BL/6 mice bearing ABPS tumors treated with vehicle/immunoglobulin G control (n = 11), DT (n = 12), PD-1 (n = 11) and DTP (n = 12; two-tailed Wilcoxon rank sum test, data are presented as mean values ± s.e.m.). d, Representative images of CD3+CD8+ T cells in ABPS tumors. e, Percentage of CD3+CD8+ T cells in ABPS tumors across the groups control (n = 10), DT (n = 10), PD-1 (n = 11) and DTP (n = 9; two-tailed Wilcoxon rank sum test, error bars represent s.e.m.). Ctrl, control; DTP, dabrafenib/trametinib/panitumumab; DP, dabrafenib/panitumumab; TP, trametinib/panitumumab.
